DUBLIN, Ireland, Jan. 5, 2015 (GLOBE NEWSWIRE) -- via PRWEB - DS102 was tested in an In Vivo Efficacy STAM™ model, an indication specific standard for NASH, over two different time periods, all of which demonstrated a clear potential for the treatment of NASH with DS102. The STAM™ model is created by a combination of chemical and dietary interventions in C57BL/6 mice.
Treatment with DS102 statistically significantly decreased the non-alcoholic fatty liver disease activity score (NAS), a clinical endpoint for assessing the activity of NASH. Importantly, DS102 also showed a statistically significant decrease in both liver fibrosis (a critical endpoint in liver disease and marker of organ deterioration) and alanine aminotransferase (ALT), a liver injury marker. The significant anti-NASH effects were consistently reproducible.
A programme of toxicology studies carried out to date in two animal species confirms the excellent safety profile of the compound.
The results support progressing DS102 into Phase I clinical trials in 2015 with a view to its commercial launch as a safe and effective treatment for NASH, liver disease and other fibrotic indications.
About Dignity Sciences
Dignity Sciences, headquartered in Dublin, Ireland, is a privately held biopharmaceutical company specialising in developing bioactive lipid compounds. The Company's first generation compound DS107 has shown to be clinically active topically in Atopic Dermatitis (Phase IIa) and is also being developed as an oral treatment for inflammatory skin disorders.
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/01/prweb12421062.htm